Table 4.
Pharmacology of glycoprotein IIb/IIIa inhibitors
| Abciximab | Eptifibatide | Tirofiban | |
|---|---|---|---|
| Trade name | ReoPro | Integrilin | Aggrastat |
| Molecule | Fragment antigen binding (Fab) 7E3 | Synthetic peptide | Non-peptide mimetic |
| Molecular weight (Da) | ~50,000 | ~800 | ~500 |
| Stoichiometry (drug to glycoprotein IIb/IIIa) | ~1.5:1 | >>100:1 | >>100:1 |
| Binding | Non-competitive | Competitive | Competitive |
| Half-life (h) | Plasma: 10–15 | Plasma: 2.0–2.5 | Plasma: 2.0–2.5 |
| Biologic: 12–24 | Biologic = plasma | Biologic = plasma | |
| PCI dosing | Bolus: 250 μg/kg | Bolus: 180 μg/kg* plus 180 μg/kg (after 10 min) | Bolus: 25 μg/kg |
| Infusion: 0.125 μg/kg/min (12 h) | Infusion: 2 μg/kg/min (12–24 h)‡ | Infusion: 0.15 μg/kg/min (up to 18 h) | |
| Renal adjustment | No | Bolus: 180 μg/kg | Bolus: 25 μg/kg |
| Infusion: 1 μg/kg/min (12–24 h) | Infusion: 0.075 μg/kg/min (up to 18 h) |
PCI percutaneous coronary intervention, Da dalton